$GILD News Selling in growth-stock leaders continues

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2013 at 9:38 PM

$GILD News

Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Gilead ends leukemia study after positive results 4:10 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 4:06 p.m. Oct. 9, 2013 - Wallace Witkowski
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
Charting a market divergence 10:21 a.m. Aug. 22, 2013 - Michael Ashbaugh
Earnings help McKesson, hospitals; FDA ruling hits Vertex, aids Gilead 9:52 a.m. July 26, 2013 - Russ Britt
S&P 500 up another 5% in 2013: J.P. Morgan's Thomas Lee 8:36 a.m. July 26, 2013 - blogs.marketwatch.com
Gilead soars on rival Vertex's drug-ruling misfortune 4:47 p.m. July 25, 2013 - Russ Britt
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Gilead profit up 8.6% on sales growth of HIV drugs 3:37 p.m. July 25, 2013 - MarketWatch.com
Gilead profit rises, sales beat forecast 3:19 p.m. July 25, 2013 - Russ Britt

'Mad Money' Lightning Round: Don't Sell Sirius 6:00 a.m. Today - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:17 p.m. Nov. 8, 2013 - TheStreet.com
Gilead Vs. Challengers In The Hepatitis C Race 7:00 a.m. Nov. 7, 2013 - Seeking Alpha
Roche Pacing the Field in the Biotech Race 6:00 a.m. Nov. 6, 2013 - TheStreet.com
U.S. Launch of Actelion's Opsumit - Analyst Blog 4:30 p.m. Nov. 5, 2013 - Zacks.com
Ligand Pharmaceuticals On Pace For Annual Profit 4:25 p.m. Nov. 5, 2013 - Investors Business Daily
Analysts: Gilead Likely to Lead HCV Treatment and 3 More Research Notes to Read 11:25 a.m. Nov. 5, 2013 - Wall St. Cheat Sheet
Gilead Sciences Inc Continues With Buy Recommendation 9:00 a.m. Nov. 5, 2013 - TheStreet.com
UBS Adds Six Top Alpha Preference List Stocks to Buy for 2014 7:34 a.m. Nov. 5, 2013 - 247WallSt.com
Stock Splits Rekindle a Polarizing Debate 8:44 p.m. Nov. 4, 2013 - WSJ.com
Top-Performing Mutual Funds Like Facebook 5:01 p.m. Nov. 4, 2013 - Investors Business Daily
Bristol-Myers Seeks Japanese Approval - Analyst Blog 2:30 p.m. Nov. 4, 2013 - Zacks.com
Protect Your Investments Against a Bubble, Know What Makes a Bubble 10:28 a.m. Nov. 4, 2013 - TheStreet.com
Benzinga's Top #PreMarket Losers 7:37 a.m. Nov. 4, 2013 - benzinga.com
Invest In Gilead Sciences For Long-Term Hepatitis C Franchise 2:13 a.m. Nov. 4, 2013 - Seeking Alpha
Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV 4:15 p.m. Nov. 2, 2013 - benzinga.com
Gilead Announces Promising Phase 2 HCV Treatment Results in Liver Transplant Patients 4:12 p.m. Nov. 2, 2013 - benzinga.com
Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex 6:40 a.m. Nov. 2, 2013 - 247WallSt.com
Jim Cramer's 6 Stocks in 60 Seconds: VRTX GTLS YELP AVD Q GRPN (Update 1) 5:20 p.m. Nov. 1, 2013 - TheStreet.com
Bull of the Day: Pharmacyclics (PCYC) - Bull of the Day 4:15 a.m. Oct. 31, 2013 - Zacks.com

S.F. Voters Repudiate Gilead, Other Pharma's Greed with Prop. D Victory 7:47 p.m. Nov. 7, 2013 - BusinessWire
Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting 9:00 a.m. Nov. 7, 2013 - BusinessWire
Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals, ViroPharma, and MannKind 8:00 a.m. Nov. 6, 2013 - PR Newswire
Under AAAResearchReports.com Microscope: Gilead Sciences Inc., NPS Pharma Inc., Halozyme Therapeutics Inc., and InterMune Inc. 11:14 a.m. Nov. 4, 2013 - PR Newswire
Quarterly Financial Reports, Clinical Study Results, and R&D Events for the Investment Community - Research Report on Gilead Sciences, Clovis, Theravance, Charles River, and Acorda 8:00 a.m. Nov. 4, 2013 - PR Newswire
Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV 9:01 a.m. Nov. 2, 2013 - BusinessWire
Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation 9:01 a.m. Nov. 2, 2013 - BusinessWire
Dun & Bradstreet CEO Sara Mathew Named Top S&P 500 Wealth Creator in 2013 8:30 a.m. Oct. 31, 2013 - PR Newswire
Sector Leaders Briefing & Capital Raise News: Muscle Warfare, Baidu, Herblife, Gilead Sciences and ARIAD 9:08 a.m. Oct. 30, 2013 - PR Newswire
Gilead Sciences Announces Third Quarter 2013 Financial Results 4:02 p.m. Oct. 29, 2013 - BusinessWire
Critical Alerts For Gilead Sciences, Trina Solar, T Rowe Price, Suncor Energy, and Morgan Stanley Released By InvestorsObserver 9:31 a.m. Oct. 29, 2013 - PR Newswire
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022 9:00 a.m. Oct. 28, 2013 - PR Newswire
FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection 4:43 p.m. Oct. 25, 2013 - BusinessWire
Gilead Sciences to Release Third Quarter 2013 Financial Results on Tuesday, October 29, 2013 5:00 p.m. Oct. 22, 2013 - BusinessWire
Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics 8:00 a.m. Oct. 22, 2013 - PR Newswire
Innovative Biotechs Making Strides In Healthcare Sector: Alliqua, MiMedx, Organovo, Anacor Pharmaceuticals, Pfizer 9:05 a.m. Oct. 21, 2013 - PR Newswire
Insider Trading Tips for Google, Rite Aid, American Express, Advanced Micro Devices, J.C. Penney, and Ariad Pharmaceuticals 8:55 a.m. Oct. 21, 2013 - PR Newswire
Gilead's Single Tablet HIV Regimen Stribild(R) Demonstrates Durable Viral Suppression Through Three Years of Therapy 3:10 a.m. Oct. 16, 2013 - BusinessWire
GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) in Patients with Chronic Hepatitis B Virus Infection 7:00 a.m. Oct. 15, 2013 - Thomson Reuters ONE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Corgi Re Modernizes Reinsurance with Tech-Focus

Amidst the hullabaloo of the reinsurance world, Corgi Insurance is attempting something rather bold. They're flinging open the doors to innovation with a new brainchild, Corgi Re, promising to shake off the dust from an industry that still clings to the bygone era of spreadsheets and marathon underwriting cycles. The aim? Fire up modern underwriting technology and...

Intrigue Over Guadalupe River Property Bid

Straight up, a chance like this doesn't float by every day. The Guadalupe River portfolio, with its mix of entertainment, hospitality, and commercial assets up for grabs in New Braunfels, Texas, is the talk of the investor town. If you've got deep pockets and a keen eye for opportunities, you're gonna want a piece of this pie before the September 22 bid deadline hits. The...

Geron Faces Legal Woes: Investors Watch for Fallout

Legal Storm Brewing Around Geron Corporation Ah, the familiar smell of trouble in corporate paradise, and this time it's drifting from Geron Corporation (NASDAQ: GERN). If you've got your chips on the table with these guys, you'd better pony up and listen up. Kuehn Law, PLLC is lighting a fire under Geron's board, snooping on whether their head honchos scuttled their...

Epson & The Photo Managers Highlight Memories in Sept.

A Focus on Memory Preservation I remember a time when you kept memories in photo albums, dusty boxes in basements. Now, folks aim to digitize those moments before they're lost forever. With September here, Epson and The Photo Managers are telling us it's time for action. And hey, the campaign’s got a catchy name, 'One Photo, One Story.' Simple, yet it urges us all to...

Qingdao-Yerevan Collaboration: New Strategic Heights

Qingdao and Yerevan: More Than Just a Port of Call Who would have thought? An Armenian ambassador talking shop in a Chinese port city isn't your everyday headline, but let me tell you, it's big news if you're watching global growth. Armenian Ambassador Vahe Gevorgyan's recent spiel in Qingdao might not turn heads on Wall Street, but there's more under the hood than meets...

Indico Breach May Expose Thousands to Identity Theft

Data Breach Unsettles Indico's Operations Well, this is the kind of headache nobody wants on their spreadsheet—the unpleasant fallout from a significant data breach is rocking Indico Data Solutions. When you hear words like 'unauthorized party' and 'exposed sensitive personal information,' it ought to make investors sit up and pay attention. On May 7, 2026, Indico, the...

PGI's Award-Winning Febreze Cabin Air Filters Shines Again

A Breath of Fresh Air for the Auto Aftermarket How often do you even think about the quality of air inside your vehicle? If you're like most folks, it's not often. But Premium Guard Inc. (PGI) has been busy changing that narrative. Their Febreze Cabin Air Filters just snagged the 2026 MOTOR Top 20 Awards, proving that they're not just a pretty face in the automotive...

Viventium's New Healthcare Platform: A Game Changer

Revolution in Workforce Management for Healthcare When a healthcare company like Viventium decides to expand its human capital management (HCM) platform, you've got to sit up and take notice, especially in a field that's been biting its nails over workforce headaches for years. Staffing shortages, growing compliance hurdles, and labor costs squeezing tighter than...

Battling Razor Bumps: Breaking a Persistent Cycle

Understanding Razor Bumps: More Than a Cosmetic Annoyance Crossing Great Neck this morning, I stumbled across a curious release from Laser by Aleya. Apparently, the problem with those pesky razor bumps plaguing many isn't just skin-deep. For some, especially those with coarse or curly hair, each razor stroke starts a relentless cycle of irritation that's as grinding as...

PepsiCo Joins AAG in 7-Year Multimillion-Dollar Deal

The sports world isn’t just about the scores on the field; it’s also about the names and logos plastered everywhere you look. And here comes PepsiCo, striding confidently into the Arizona Athletic Grounds (AAG) arena with the gusto of a heavyweight looking to make some serious gains. Big Brand, Big Moves: What This Means for AAG This isn’t your run-of-the-mill...